第二剂ChAdOx1 nCoV19疫苗接种后疫苗诱导的免疫性血栓性血小板减少症:严重程度较低但仍存在问题
该研究描述了澳大利亚第二剂AZD1222疫苗接种后确诊疫苗诱导的免疫性血栓性血小板减少症(VITT)的临床病理特征,并与第一剂后确诊病例比较。62例转诊患者中15例确诊,发生2例死亡,死亡者接种间隔均小于30天。与第一剂相比,第二剂病例更多为男性、血小板计数更高、D-二聚体更低且不寻常部位血栓形成更少。
要点
- 第二剂AZD1222疫苗接种后仍可发生VITT,62例疑似中15例确诊。
- 确诊者中位就诊时间13天,血小板计数116×10^9/L,D-二聚体升高14.5倍正常上限。
- 发生2例死亡,死亡者接种间隔均小于30天。
核心结论
- VITT是第二剂AZD1222疫苗接种的并发症,虽然临床病理特征较第一剂后严重程度较低,但伴有合并因素的患者仍发生了死亡。
研究设计与样本
- 对澳大利亚集中检测中心在第二剂AZD1222疫苗接种后4-42天内转诊的临床疑似VITT(血小板减少、D-二聚体>5倍正常上限和血栓形成)连续病例进行血小板活化确诊检测,最终分类由专家咨询委员会裁定。
- 对第二剂后确诊病例进行描述性统计,并与第一剂后确诊病例进行比较分析。
主要发现
- 62例转诊患者中,15例显示抗体介导的血小板活化,符合第二剂AZD1222疫苗接种后VITT;其中4例免疫测定阳性。
- 中位就诊时间为13天(范围1-53),血小板计数116×10^9/L(范围63-139),D-二聚体升高14.5倍正常上限(IQR 11,26)。
- 发生2例死亡,每例的接种间隔均小于30天。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but established complication of 1st dose ChAdOx1 nCoV19 vaccination (AZD1222), however this complication after dose 2 remains controversial. OBJECTIVES: To describe the clinicopathological features of confirmed cases of VITT post dose 2 AZD1222 vaccination in Australia, and to compare this cohort to confirmed cases of VITT post 1st dose. METHODS: Sequential cases of clinically suspected VITT (thrombocytopenia, D-Dimer > 5x upper limit normal and thrombosis) within 4-42 days of dose 2 AZD1222 referred to Australia's centralised testing centre underwent platelet activation confirmatory testing in keeping with the national diagnostic algorithm. Final classification was assigned after adjudication by an expert advisory committee. Descriptive statistics were performed on this cohort and comparative analyses carried out on confirmed cases of VITT after 1st and 2nd dose AZD1222. RESULTS: Of 62 patients referred, 15 demonstrated presence of antibody mediated platelet activation consistent with VITT after dose 2 AZD1222. Four were immunoassay positive. Median time to presentation was 13 days (range 1-53) platelet count 116x10^9/L (range 63-139) and D-dimer elevation 14.5xULN (IQR 11, 26). Two fatalities occurred. In each, the dosing interval was less than 30 days. In comparison to 1st dose, dose 2 cases were more likely to be male (OR 4.6, 95% CI 1.3-15.8, p = 0.03), present with higher platelet counts (p = 0.05), lower D-Dimer (p = 01) and less likely to have unusual site thromboses (OR 0.14, 95% CI 0.04-0.28, p = 0.02). CONCLUSIONS: VITT is a complication of dose 2 AZD1222 vaccination. Whilst clinicopathological features are less severe, fatalities occurred in patients with concomitant factors.
引用
- Clarke L, Brighton T, Chunilal SD, et al. Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem. Vaccine. 2023. PMID: 37085453. doi:10.1016/j.vaccine.2023.03.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。